HCPCS Level II code J7192 denotes recombinant Factor VIII (antihemophilic factor) billed per international unit when no more specific product code is used. Factor VIII products are essential biologic therapies for patients with hemophilia A and certain bleeding disorders; accurate coding affects clinical documentation, inventory management, and payer reimbursement for high-cost biologic infusions. Nationally, consistent use of a per-i.u. code like J7192 matters for cost tracking and claims processing when brand- or formulation-specific codes are not reported.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks and context on billing practices for recombinant Factor VIII when per-i.u. reporting is employed, an overview of payer coverage considerations, and clinical context for the service line. The publication outlines typical sites of service for administration, common billing modifiers used in practice (data provided separately), and areas where policy updates or payer-specific rules may affect claims. Data not available in the input is noted where relevant. This summary is written for a national audience seeking clarity on coding, billing pathways, and the administrative implications of using HCPCS Level II code J7192.